"Anti-obesity medicines "without a doubt have revolutionized this landscape for sustainable weight loss," Anegawa said in an interview with Bloomberg Radio. "But for the millions of Americans taking these medications, lasting success is really not often achievable without having that anchor in behavioral change.""
"With the new category of drugs, "the weight-loss outcomes are so much better, and we listen to our users, our patients," said Linda Anegawa, Noom's chief of medicine. "Patients are asking, 'How can Noom support us more?'""
"Patients who took the highest dose of Mounjaro, a diabetes drug from Eli Lilly & Co. that's in testing as an obesity treatment, lost an average of 50 pounds. Many one-time dieters see those results as far more reliable and easily obtained than from traditional habit-changing programs."
Noom Inc. is expanding beyond its psychology-focused weight-loss approach by launching Noom Med, which prescribes GLP-1 obesity drugs such as Novo Nordisk's Wegovy for approximately $120 per month. This move reflects the weight-loss industry's broader shift toward incorporating highly effective pharmaceutical interventions alongside traditional behavioral programs. GLP-1 drugs help patients feel fuller and eat less with minimal side effects, with some patients losing up to 50 pounds on higher doses. Noom's chief of medicine emphasizes that while these medications revolutionize weight-loss outcomes, lasting success requires combining pharmaceutical treatment with behavioral change guidance. Noom Med will initially operate in 32 states including New York, Texas, and California, with expansion planned.
#glp-1-obesity-drugs #weight-loss-pharmaceuticals #behavioral-health-integration #noom-med-launch #digital-health-expansion
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]